PO0024 - On the issue of adherence to therapy with factor Xa inhibitors in real clinical practice

Wednesday, July 13, 2022

1:00 PM – 2:00 PM

Location: ExCel Center, ICC Capital Suite Room 1

Presenting Author(s)

Nadezda A. Vorobyeva, PhD

ptofessor
Northern State Medical University, Health Ministry of Russian Federation; 51 Troitsky Avenue, Arkhangelsk
Arckhangelsk, Arkhangelsk, Russia

Co-Author(s)

AV

Alyona I. Vorobyeva

anticoagulant clinic doctor
Northern State Medical University, Health Ministry of Russian Federation; 51 Troitsky Avenue, Arkhangelsk 163000, Russia
Archangelsk, Arkhangelsk, Russia

Background: In comorbid and elderly patients taking DOACs, it is important to maintain adherence to both antithrombotic therapy itself and to concomitant pharmacotherapy, as otherwise it may lead to progression pathology, fatal complications, naturally, to an increase in mortality, an increase
health care costs in general.

Aims: The article is to evaluate adherence to therapy with direct factor Xa inhibitors in clinical practice.

Methods: An study included patients receiving a antithrombotic therapy with factor Xa inhibitors (n = 50), who were observed at the Regional Center for Antithrombotic Therapy of the City Clinical Hospital, Arkhangelsk. To confirm the fact of taking DOAC and compliance with the therapy, the study determined peak concentration of DOAC in blood plasma and analyzed whether a patient had completed training at the DOAC School. To assess the patient compliance with the antithrombotic therapy, laboratory monitoring of the peak concentration of DOAC was carried out, depending on the fact of training at the School.

Results: The study showed no statistically significant difdrug and did not attendferences in the concentration of rivaroxaban and apixaban in patients who were trained at the DOAC School and did not attend the class. Laboratory monitoring of the peak concentration of DOACs in 10% patients showed they had no DOAC in blood plasma. This indicated that the drug was not being taken. It is important to note that 5 patients concealed from the doctor the fact that they did not take the the School. Prescription of potentially non-recommended drugs according to «STOPP» criteria (2015 ed.) was identified in 4% of patients

Conclusion(s): Events clarifying the importance of antithrombotic therapy are advisable to increase patient compliance and, accordingly, the effectiveness and safety of this type of drug therapy. In some cases, to determine the peak concentration of the drug is recommended to assess compliance with the DOAC therapy.